Baird Financial Group Inc. boosted its holdings in Stryker Co. (NYSE:SYK) by 1.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 77,582 shares of the medical technology company’s stock after buying an additional 889 shares during the period. Baird Financial Group Inc.’s holdings in Stryker were worth $13,100,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of SYK. Kaizen Advisory LLC increased its position in shares of Stryker by 142.6% during the second quarter. Kaizen Advisory LLC now owns 752 shares of the medical technology company’s stock valued at $127,000 after purchasing an additional 442 shares during the period. CX Institutional bought a new stake in shares of Stryker during the second quarter valued at approximately $133,000. NumerixS Investment Technologies Inc bought a new stake in shares of Stryker during the second quarter valued at approximately $135,000. Bruderman Asset Management LLC bought a new stake in shares of Stryker during the first quarter valued at approximately $152,000. Finally, Ostrum Asset Management bought a new stake in shares of Stryker during the first quarter valued at approximately $160,000. 75.12% of the stock is currently owned by institutional investors.

Shares of SYK stock opened at $169.75 on Friday. The company has a current ratio of 1.83, a quick ratio of 1.15 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $62.85 billion, a P/E ratio of 26.16, a P/E/G ratio of 2.36 and a beta of 0.59. Stryker Co. has a one year low of $138.94 and a one year high of $179.84.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, July 24th. The medical technology company reported $1.76 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.73 by $0.03. The business had revenue of $3.32 billion for the quarter, compared to analyst estimates of $3.31 billion. Stryker had a return on equity of 26.93% and a net margin of 8.28%. Stryker’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.53 EPS. research analysts expect that Stryker Co. will post 7.25 earnings per share for the current fiscal year.

SYK has been the topic of a number of research reports. Zacks Investment Research cut Stryker from a “buy” rating to a “hold” rating in a research report on Friday, May 18th. ValuEngine cut Stryker from a “buy” rating to a “hold” rating in a research report on Tuesday, June 12th. Cantor Fitzgerald restated a “hold” rating and set a $170.00 price objective on shares of Stryker in a research report on Wednesday, June 13th. Sanford C. Bernstein initiated coverage on Stryker in a research report on Wednesday, June 27th. They set a “market perform” rating and a $177.00 price objective on the stock. Finally, BMO Capital Markets restated a “hold” rating and set a $174.00 price objective on shares of Stryker in a research report on Thursday, July 12th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $177.25.

In other Stryker news, VP Katherine Ann Owen sold 37,866 shares of the business’s stock in a transaction on Wednesday, September 5th. The stock was sold at an average price of $166.84, for a total value of $6,317,563.44. Following the transaction, the vice president now owns 11,367 shares of the company’s stock, valued at $1,896,470.28. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.40% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

See Also: Book Value Per Share in Stock Trading

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.